These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7652486)

  • 21. The use of tumor markers in the management of patients with gynecologic carcinomas.
    Berchuck A; Boente MP; Bast RC
    Clin Obstet Gynecol; 1992 Mar; 35(1):45-54. PubMed ID: 1544249
    [No Abstract]   [Full Text] [Related]  

  • 22. [Cytokines as tumor markers in breast cancer].
    Ławicki S; Mroczko B; Szmitkowski M
    Postepy Hig Med Dosw; 2003; 57(4):455-63. PubMed ID: 14626202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of tumour markers in ascitic fluid and serum: are measurements of ascitic tumour markers a futile attempt?
    Tuzun Y; Celik Y; Bayan K; Yilmaz S; Dursun M; Canoruc F
    J Int Med Res; 2009; 37(1):79-86. PubMed ID: 19215676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between the tumour-associated antigen 90K and cytokines in the circulation of persons infected with human immunodeficiency virus.
    Senaldi G; Peakman M; Natoli C; Hussain MJ; Gallati H; McManus T; Vergani D; Iacobelli S
    J Infect; 1994 Jan; 28(1):31-9. PubMed ID: 8163831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Tumour markers of pancreatic cancer (tumour associated antigens)].
    Groblewska M; Mroczko B; Szmitkowski M
    Pol Arch Med Wewn; 2005 Jun; 113(6):585-93. PubMed ID: 16454450
    [No Abstract]   [Full Text] [Related]  

  • 26. [Gender differences in the use of tumour markers].
    Moreno-Campoy EE; Mérida-De la Torre FJ; Martos-Crespo F; Plebani M
    Rev Calid Asist; 2015; 30(6):327-34. PubMed ID: 26410238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct influences of pro-inflammatory cytokines (IL-1beta, TNF-alpha, IL-6) on the proliferation and cell-surface antigen expression of cancer cells.
    Kuninaka S; Yano T; Yokoyama H; Fukuyama Y; Terazaki Y; Uehara T; Kanematsu T; Asoh H; Ichinose Y
    Cytokine; 2000 Jan; 12(1):8-11. PubMed ID: 10623436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic factors in pulmonary metastasectomy: spotlight on molecular and radiological markers.
    Schweiger T; Lang G; Klepetko W; Hoetzenecker K
    Eur J Cardiothorac Surg; 2014 Mar; 45(3):408-16. PubMed ID: 23729747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatocellular carcinoma tumour markers: current role and expectations.
    Rich N; Singal AG
    Best Pract Res Clin Gastroenterol; 2014 Oct; 28(5):843-53. PubMed ID: 25260312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cytokines. The role of cytokines in colorectal cancer].
    Mroczko B; Lawicki S; Szmitkowski M
    Pol Arch Med Wewn; 2002 Oct; 108(4):1001-9. PubMed ID: 12647698
    [No Abstract]   [Full Text] [Related]  

  • 31. [Serum cytokines in patients with ovarian cancer and benign ovarian cysts].
    Nowak M; Szpakowski M; Malinowski A; Wieczorek A; Maciołek-Blewniewska G; Wilczyński JR; Szpakowski A; Wierzbicka E; Małafiej E; Oszukowski P
    Ginekol Pol; 2001 Dec; 72(12A):1444-8. PubMed ID: 11883294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of the hematopoietic cytokines SCF, IL-3, GM-CSF and M-CSF in the diagnosis of pancreatic and ampullary cancer.
    Vasiliades G; Kopanakis N; Vasiloglou M; Zografos G; Margaris H; Masselou K; Kokosi E; Liakakos T
    Int J Biol Markers; 2012 Oct; 27(3):e186-94. PubMed ID: 22865301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased plasma concentrations of tumour markers in the absence of neoplasia.
    Trapé J; Filella X; Alsina-Donadeu M; Juan-Pereira L; Bosch-Ferrer Á; Rigo-Bonnin R;
    Clin Chem Lab Med; 2011 Oct; 49(10):1605-20. PubMed ID: 21892908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancers Screening in an Asymptomatic Population by Using Multiple Tumour Markers.
    Wang HY; Hsieh CH; Wen CN; Wen YH; Chen CH; Lu JJ
    PLoS One; 2016; 11(6):e0158285. PubMed ID: 27355357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RATIONAL USE OF SERUM TUMOUR MARKERS IN DIAGNOSTICS AND TREATMENT OF SOLID TUMOURS.
    Plavetić ND; Gnjidić M; Kulić A; Ivić M; Kukec I; Vidović M
    Lijec Vjesn; 2016; 138(3-4):85-92. PubMed ID: 30146854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum tumour markers in lung cancer: history, biology and clinical applications.
    Ferrigno D; Buccheri G; Biggi A
    Eur Respir J; 1994 Jan; 7(1):186-97. PubMed ID: 8143820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pitfalls in the interpretation of tumour markers.
    Oleesky DA; Fifield R
    BMJ; 1996 Jan; 312(7024):183. PubMed ID: 8563553
    [No Abstract]   [Full Text] [Related]  

  • 38. Tumour stem cells in schwannoma: A review.
    Cutfield SW; Wickremesekera AC; Mantamadiotis T; Kaye AH; Tan ST; Stylli SS; Itineang T
    J Clin Neurosci; 2019 Apr; 62():21-26. PubMed ID: 30626543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating biomarkers in malignant melanoma.
    Alegre E; Sammamed M; Fernández-Landázuri S; Zubiri L; González Á
    Adv Clin Chem; 2015; 69():47-89. PubMed ID: 25934359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum tumour markers: implications of discordant results.
    Howaritz JH
    Dis Markers; 1995 Mar; 12(2):81-3. PubMed ID: 7614784
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.